Published in N Engl J Med on October 18, 1979
Comparison of anticoagulant control among patients attending general practice and a hospital anticoagulant clinic. Br J Gen Pract (1993) 4.89
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest (1990) 2.14
Anticoagulation control with warfarin by junior hospital doctors. J R Soc Med (1987) 1.90
Anticoagulants in venous thromboembolism. BMJ (1988) 1.77
Therapeutic ranges in anticoagulant administration. Br Med J (Clin Res Ed) (1985) 1.40
Diagnosis of pulmonary embolism. CMAJ (2003) 1.31
Oral anticoagulants reassessed. Br Med J (Clin Res Ed) (1982) 1.13
Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism. Thromb J (2013) 1.05
Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. J Clin Invest (1987) 0.97
Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One (2012) 0.96
Treatment options for venous thromboembolism: lessons learnt from clinical trials. Thromb J (2014) 0.95
Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients. Can Med Assoc J (1982) 0.90
Treatment and secondary prevention of venous thromboembolism in cancer. Br J Cancer (2010) 0.88
Sex differences in patients receiving anticoagulant therapy for venous thromboembolism. Medicine (Baltimore) (2014) 0.86
Venous thromboembolism: A problem in the Indian/Asian population? Indian J Urol (2009) 0.85
Clinical disagreement: II. How to avoid it and how to learn from one's mistakes. Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario. Can Med Assoc J (1980) 0.83
New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities. Drugs (2014) 0.82
High incidence of complications from enoxaparin treatment after arthroplasty. Clin Orthop Relat Res (2009) 0.81
Sulfation patterns determine cellular internalization of heparin-like polysaccharides. Mol Pharm (2013) 0.80
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2016) 0.80
Negative D-dimer result to exclude recurrent deep venous thrombosis: a management trial. Ann Intern Med (2004) 0.80
Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach. Curr Treat Options Cardiovasc Med (2013) 0.79
Long-term anticoagulation. Indications and management. West J Med (1989) 0.76
Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies. Acad Emerg Med (2015) 0.75
A practical heparin reduction algorithm: execution and operational characteristics. J Clin Pathol (1985) 0.75
Hematologic and oncologic complications in the critically ill child. Yale J Biol Med (1984) 0.75
Anticoagulation in venous thrombosis. J R Soc Med (1996) 0.75
Enoxaparin treatment of spontaneous deep vein thrombosis in a chronically catheterized rhesus macaque (Macaca mulatta). J Am Assoc Lab Anim Sci (2009) 0.75
Treatment of thromboembolic disease. J R Soc Med (1982) 0.75
The treatment of deep vein thrombosis in the pelvis and leg. Dtsch Arztebl Int (2008) 0.75
Anticoagulation in patients with thromboembolic disease. Thorax (2001) 0.75
Treatment of a patient with an undefined hypercoagulable state with long-term low-molecular-weight heparin. West J Med (1996) 0.75
Medical management of venous thromboembolic disease. Ochsner J (2000) 0.75
New anticoagulants for the treatment of venous thromboembolism. J Bras Pneumol (2016) 0.75
Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines. Vasc Specialist Int (2016) 0.75
The effect of the fibrinolytic enzyme FIIa from Agkistrodon acutus venom on acute pulmonary thromboembolism. Acta Pharmacol Sin (2011) 0.75
Novel Anticoagulant Therapy of Venous Thromboembolism: Current Status and Future Directions. Ann Vasc Dis (2017) 0.75
Evidence based medicine. BMJ (1995) 21.24
The Burlington randomized trial of the nurse practitioner. N Engl J Med (1974) 17.02
Contribution of adhesion to bacterial persistence in the mouse urinary tract. Infect Immun (1983) 14.71
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA (1999) 12.75
Controversy in counting and attributing events in clinical trials. N Engl J Med (1979) 7.25
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 6.86
Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol (1991) 6.55
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
Management of anticoagulation before and after elective surgery. N Engl J Med (1997) 5.10
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost (2000) 4.81
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med (1996) 4.70
Determining optimal therapy--randomized trials in individual patients. N Engl J Med (1986) 4.49
Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med (1997) 4.47
A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol (2001) 4.39
The Burlington randomized trial of the nurse practitioner: health outcomes of patients. Ann Intern Med (1974) 4.37
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation (2000) 4.12
Genetics of digalactoside-binding adhesin from a uropathogenic Escherichia coli strain. Infect Immun (1983) 4.03
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med (1993) 3.67
A new type of cardioselective adrenoceptive blocking drug. Br J Pharmacol (1973) 3.65
The Drosophila ninaE gene encodes an opsin. Cell (1985) 3.65
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Inhibition of experimental ascending urinary tract infection by an epithelial cell-surface receptor analogue. Nature (1982) 3.50
Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet (2000) 3.50
An empirical demonstration of Berkson's bias. J Chronic Dis (1978) 3.48
Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science (1984) 3.47
Accuracy of clinical assessment of deep-vein thrombosis. Lancet (1995) 3.45
Limitations of impedance plethysmography in the diagnosis of clinically suspected deep-vein thrombosis. Ann Intern Med (1993) 3.40
A clinician's guide for conducting randomized trials in individual patients. CMAJ (1988) 3.35
Effect of bromhexine on ventilatory capacity in patients with a variety of chest diseases. Lancet (1969) 3.34
Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med (2000) 3.32
Molecular cloning and physical characterization of a chromosomal hemolysin from Escherichia coli. Infect Immun (1983) 3.30
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med (1982) 3.16
Inappropriate reattendances in out-patient departments. J Public Health Med (1992) 3.14
Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med (1998) 3.09
The cloned dopa decarboxylase gene is developmentally regulated when reintegrated into the Drosophila genome. Cell (1983) 3.08
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med (1986) 3.00
Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med (1985) 2.99
Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables. Biometrics (1977) 2.87
Health services research for decision-makers: the use of the Delphi technique to determine health priorities. J Health Polit Policy Law (1977) 2.79
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1992) 2.76
A standard heparin nomogram for the management of heparin therapy. Arch Intern Med (1991) 2.69
Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med (1996) 2.69
Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation (1996) 2.69
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. Eur Heart J (2004) 2.67
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med (1990) 2.63
A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med (1972) 2.60
Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med (1998) 2.49
Assessing the effectiveness of community screening programs. JAMA (1984) 2.45
The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol (1999) 2.44
Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet (1988) 2.44
Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice. Infect Immun (1984) 2.35
Doctors' perceptions of pressure from patients for referral. BMJ (1991) 2.35
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol (2000) 2.35
Establishing a therapeutic range for heparin therapy. Ann Intern Med (1993) 2.31
Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial. Ann Intern Med (1997) 2.28
Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med (1989) 2.28
Managing oral anticoagulant therapy. Chest (2001) 2.25
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25
Retroid virus genome replication. Adv Virus Res (1987) 2.23
Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med (1992) 2.23
A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A (2000) 2.20
Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med (1973) 2.17
Improving searching skills and evidence retrieval. J R Coll Physicians Lond (1999) 2.17
The Dr hemagglutinin, afimbrial adhesins AFA-I and AFA-III, and F1845 fimbriae of uropathogenic and diarrhea-associated Escherichia coli belong to a family of hemagglutinins with Dr receptor recognition. Infect Immun (1990) 2.14
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest (1990) 2.14
Dynamic microscopy of nanoscale cluster growth at the solid-liquid interface. Nat Mater (2003) 2.07
Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost (2015) 2.07
How should results from completed studies influence ongoing clinical trials? The CAFA Study experience. Ann Intern Med (1991) 2.06
Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation (2000) 2.05
Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. N Engl J Med (1981) 2.04
Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation (2001) 2.01
Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med (1991) 2.01
Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J Virol (2000) 2.00
Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. J Thromb Haemost (2013) 1.97
Angina pectoris with normal coronary arteries. Transvenous myocardial biopsy in diagnosis. Lancet (1974) 1.97
A hemagglutinin of uropathogenic Escherichia coli recognizes the Dr blood group antigen. Infect Immun (1988) 1.95
Persistent post-splenectomy thrombocytosis and thrombo-embolism: a consequence of continuing anaemia. Br J Haematol (1966) 1.94
Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol (1988) 1.93
Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. Ann Intern Med (2001) 1.93
Model for vesicular stomatitis virus. J Virol (1972) 1.92
Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest (1985) 1.92